Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer

被引：0
|
作者：
Michalaki, Vasiliki
Theodosopoulos, Thedosios
Vezakis, Antonios
Papaconstantinou, Ioannis
Kontis, Ioannis
Dafnios, Nikolaos
Frangoulidis, George
Karandrea, Despina
Papadimitriou, Christos
机构：
[1] Natl & Kapodistrian Univ Athens, Aretaieion Hosp, Sch Med, Dept Surg 2, Athens, Greece
[2] Aretaieion Hosp, Dept Surg 2, Athens, Greece
[3] Natl & Kapodistrian Univ, Aretaieion Hosp, Dept Surg 2, Athens, Greece
[4] Univ Athens, Aretaieion Hosp, Dept Surg 2, Athens, Greece
[5] Natl & Kapodistrian Univ Athens, Aretaieion Hosp, Oncol, Dept Surg 2, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15605
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
    Chida, Keigo
    Kotani, Daisuke
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Watanabe, Jun
    Endo, Itaru
    Yoshino, Takayuki
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [3] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [4] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
  • [5] Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies
    Martinez Lago, N.
    Alonso de Castro, B.
    Varela Ponte, R.
    Reboredo Rendo, C.
    Gomez-Randulfe Rodriguez, M.
    Grana Suarez, B.
    de la Camara Gomez, J.
    Mateos Salvador, M.
    Busto Fernandez, F.
    Calleja Chucla, T.
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S106 - S107
  • [6] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
    Kotani, D.
    Kuboki, Y.
    Yasuda, K.
    Nakamura, Y.
    Kawazoe, A.
    Bando, H.
    Taniguchi, H.
    Shitara, K.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
  • [7] Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
    Takahashi, Toshiaki
    Shigeyasu, Kunitoshi
    Kondo, Yoshitaka
    Takeda, Sho
    Umeda, Hibiki
    Moriwake, Kazuya
    Kayano, Masashi
    Sakurai, Yuya
    Nakamura, Shunsuke
    Takahashi, Masafumi
    Nitta, Kaori
    Yoshida, Kazuhiro
    Matsumi, Yuki
    Michiue, Hiroyuki
    Yamamoto, Hideki
    Kishimoto, Hiroyuki
    Teraishi, Fuminori
    Shoji, Ryohei
    Kanaya, Nobuhiko
    Kashima, Hajime
    Kakiuchi, Yoshihiko
    Kuroda, Shinji
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    BMC CANCER, 2025, 25 (01)
  • [8] Safety and efficacy of trifluridine/tipiracil monotherapy in metastatic colorectal cancer
    Aparicio Rubio, C.
    Monteagudo Santolaya, E.
    Cornejo Uixeda, S.
    Prieto Castello, M.
    Antonino de la Camara, G.
    Quintana Vergara, B.
    Sanchez Alcaraz, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 373 - 374
  • [9] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Martinez-Lago, Nieves
    Calleja Chucla, Teresa
    Alonso De Castro, Beatriz
    Varela Ponte, Rafael
    Reboredo Rendo, Cristina
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Grana Suarez, Begona
    de la Camara Gomez, Juan
    Busto Fernandez, Fernando
    Mateos Salvador, Maria
    Reboredo Lopez, Margarita
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [10] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Nieves Martínez-Lago
    Teresa Calleja Chucla
    Beatriz Alonso De Castro
    Rafael Varela Ponte
    Cristina Reboredo Rendo
    Martin Igor Gomez-Randulfe Rodriguez
    Sofia Silva Diaz
    Begoña Graña Suarez
    Juan de la Cámara Gomez
    Fernando Busto Fernández
    María Mateos Salvador
    Margarita Reboredo Lopez
    Scientific Reports, 12
12345